News
1d
Zacks Investment Research on MSNNVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
A federal judge ruled in favor of a whistleblower, finding CVS’ pharmacy benefit manager Caremark overbilled Medicare for ...
CVS Caremark has been ordered to pay $95 million after a federal judge found the pharmacy benefit manager improperly inflated Medicare Part D drug prices by failing to report required pharmacy ...
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...
Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.
CVS Caremark, the PBM arm of CVS Health, has been accused of directing patients to CVS-owned pharmacies in Louisiana. RELATED STORIES. New pharmacy rules get approval as session ends.
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, ... Even with the CVS formulary change (moving away from Zepbound) putting ~200,000 patients at risk, ...
If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate.
CaremarkPCS Health Inc. got the go-ahead Thursday to litigate in federal court West Virginia’s claims that it unlawfully drove up insulin costs for the state’s employee benefits plan. The prescription ...
It's just over a week since pharmacy benefit managers CVS and Express Scripts sued the state of Arkansas over a new monopoly-busting law prohibiting PBMs—middle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results